Modulated nucleoside kinases as tools to improve the activation of therapeutic nucleoside analogues.
The use of nucleoside analogues in anticancer and antiviral treatments is often impaired by the slow intracellular activation of these drugs. This problem can be addressed by the modulation of rate-limiting enzymes in the activation pathways of the nucleoside analogues. Therapeutic strategies based on the combination of optimized activating enzymes and established nucleoside drugs promise significant improvements to traditional chemotherapy.
Monnerjahn
Christian
C
Max-Planck-Institute for Biophysical Chemistry, Department of Molecular Genetics, Am Fassberg 11, 37077 Göttingen, Germany.
Konrad
Manfred
M
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D009703:Nucleoside-Phosphate Kinase / Q000627:therapeutic use; D009705:Nucleosides / Q000138:chemical synthesis* / Q000627:therapeutic use*; D010770:Phosphotransferases / Q000138:chemical synthesis*; D011355:Prodrugs / Q000138:chemical synthesis* / Q000378:metabolism / Q000627:therapeutic use; D015202:Protein Engineering / Q000639:trends; D013329:Structure-Activity Relationship; D015215:Zidovudine / Q000627:therapeutic use
D009705:Nucleosides; D011355:Prodrugs; D015215:Zidovudine; D010770:Phosphotransferases; C021892:nucleoside phosphotransferase; D009703:Nucleoside-Phosphate Kinase; C020093:dTMP kinase